Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMPAGLIFLOZIN; LINAGLIPTIN vs ALESSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
10 mg empagliflozin/5 mg linagliptin orally once daily.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Empagliflozin: ~12.4 h (supports once-daily dosing). Linagliptin: ~12 h (terminal half-life; long binding to DPP-4 allows once-daily dosing despite short half-life).
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Empagliflozin is primarily metabolized via glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9) with minor CYP450 involvement. Linagliptin is minimally metabolized; approximately 90% is excreted unchanged via enterohepatic system (biliary excretion) and renal elimination is negligible.
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Empagliflozin: ~54% renal (unchanged), ~41% fecal (primarily unchanged parent). Linagliptin: ~80% fecal (enterohepatic circulation), ~5% renal.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Empagliflozin: ~86.2% (primarily albumin). Linagliptin: 70-80% (concentration-dependent, saturable binding to DPP-4; also albumin).
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
Empagliflozin: Vd/F ~9.6 L (0.14 L/kg; extensive tissue distribution). Linagliptin: Vd ~1000 L (14 L/kg; large due to extensive tissue binding).
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
Empagliflozin: oral bioavailability ~78% (high, unaffected by food). Linagliptin: oral bioavailability ~30% (food has no effect; low due to first-pass and saturable absorption).
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
Contraindicated if e GFR < 30 m L/min/1.73 m². Not recommended if e GFR < 45 m L/min/1.73 m². No dose adjustment for e GFR ≥ 45 m L/min/1.73 m².
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh A, B, C).
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
Safety and efficacy not established in pediatric patients.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
No dose adjustment based on age alone. Assess renal function; contraindicated if e GFR < 30 m L/min/1.73 m². Consider increased risk of volume depletion and hypotension in patients aged ≥75 years.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
None
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
Risk of pancreatitis (linagliptin),Risk of genital mycotic infections and urinary tract infections (empagliflozin),Risk of volume depletion, hypotension, and acute kidney injury (empagliflozin),Risk of ketoacidosis, including euglycemic ketoacidosis (empagliflozin),Risk of hypoglycemia when used with insulin or sulfonylureas,Risk of heart failure (linagliptin; postmarketing reports),Risk of bullous pemphigoid (DPP-4 inhibitors),Risk of severe and disabling arthralgia (DPP-4 inhibitors)
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
History of serious hypersensitivity reaction to empagliflozin, linagliptin, or any excipient,Severe renal impairment (e GFR < 30 m L/min/1.73 m²), end-stage renal disease, or dialysis (empagliflozin),Type 1 diabetes mellitus (empagliflozin; risk of ketoacidosis)
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
No significant food interactions. Alcohol may increase risk of lactic acidosis and ketoacidosis; limit intake. Avoid grapefruit juice as it may affect linagliptin metabolism (minor interaction, but caution advised).
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are maturing. Human data are limited; however, SGLT2 inhibitors are generally avoided in the second and third trimesters due to potential risk of acute kidney injury in neonates. Linagliptin: Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Human data are insufficient; however, DPP-4 inhibitors are generally considered low risk during pregnancy. Overall, combination should be avoided unless clearly needed, particularly in the second and third trimesters.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
Empagliflozin: Unknown if excreted in human milk; animal studies show excretion in milk. Due to potential for adverse effects on the developing infant (e.g., renal effects), breastfeeding is not recommended. Linagliptin: Unknown if excreted in human milk; animal studies show low levels in milk. Caution is advised. Both drugs: M/P ratio not available. Manufacturer recommends discontinuing drug or breastfeeding.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
Empagliflozin: Pregnancy alters pharmacokinetics (increased renal clearance, volume of distribution), but no specific dose adjustments are recommended due to lack of data. However, empagliflozin is contraindicated in pregnancy, particularly in the second and third trimesters. Linagliptin: No dose adjustment required based on pharmacokinetic changes in pregnancy; however, safety data are limited. Overall, alternative therapies are preferred during pregnancy.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
Empagliflozin/linagliptin should not be used in patients with type 1 diabetes or for diabetic ketoacidosis treatment. Assess renal function before initiation and periodically; e GFR <45 m L/min/1.73 m2 is a contraindication for empagliflozin. Monitor for signs of ketoacidosis, even if blood glucose is not markedly elevated. Linagliptin does not require dose adjustment for renal impairment. Genital mycotic infections and urinary tract infections are common with empagliflozin; counsel on hygiene. Temporary discontinuation of SGLT2 inhibitors is recommended before surgery or during prolonged fasting to reduce ketoacidosis risk.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
Take this medication exactly as prescribed, usually once daily with or without food.,Stay well hydrated to reduce risk of dehydration and urinary tract infections.,Report symptoms of genital itching, discomfort, or discharge promptly for possible yeast infection.,Seek immediate medical attention if you experience symptoms of ketoacidosis (nausea, vomiting, abdominal pain, confusion, unusual fatigue, difficulty breathing) even if blood sugar is normal.,Do not share this medication with others; it is not for treating type 1 diabetes.,Inform all healthcare providers that you are taking this medication, especially before surgery or procedures.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
"Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption, leading to decreased blood glucose levels. Rosoxacin, a quinolone antibiotic, may enhance the hypoglycemic effects of empagliflozin by potentiating insulin secretion or improving insulin sensitivity, which could increase the risk of hypoglycemic episodes, especially in patients with diabetes mellitus."
"Quinethazone, a thiazide-like diuretic, reduces intravascular volume and may blunt the osmotic diuretic effect of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, thereby decreasing empagliflozin's efficacy in lowering blood glucose. This interaction is mediated through volume contraction leading to reduced renal perfusion and diminished glucose excretion. Clinically, patients may experience higher-than-expected blood glucose levels, potentially compromising glycemic control."
"Concomitant use of lisinopril, an angiotensin-converting enzyme inhibitor, and empagliflozin, a sodium-glucose cotransporter-2 inhibitor, may enhance the risk of hypotension, acute kidney injury, and hyperkalemia. Lisinopril reduces angiotensin II-mediated vasoconstriction and aldosterone secretion, which can be compounded by empagliflozin-induced volume depletion and osmotic diuresis. This interaction is particularly concerning in patients with renal impairment or those on other medications affecting the renin-angiotensin-aldosterone system."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMPAGLIFLOZIN; LINAGLIPTIN vs ALESSE, answered by our medical review team.
EMPAGLIFLOZIN; LINAGLIPTIN is a DPP-4 Inhibitor that works by Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.. ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMPAGLIFLOZIN; LINAGLIPTIN and ALESSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMPAGLIFLOZIN; LINAGLIPTIN is: 10 mg empagliflozin/5 mg linagliptin orally once daily.. The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMPAGLIFLOZIN; LINAGLIPTIN and ALESSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMPAGLIFLOZIN; LINAGLIPTIN is classified as Category A/B. Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are m. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.